ASX-Dividend-Report-Banner

Davos Communications Awards - BGI Genomics Inclusive Instagram Strategy Wins Gold Recognition

December 22, 2023 11:19 AM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp
 Davos Communications Awards - BGI Genomics Inclusive Instagram Strategy Wins Gold Recognition
Image source: Kalkine Media

HONG KONG, Dec. 22, 2023 /PRNewswire/ -- BGI Genomics, the world's leading provider of integrated solutions for precision medicine, is pleased to announce winning Instagram Campaign (Gold) recognition at the Davos Communications Awards held on December 12, 2023.

Organized by the World Communications Forum Association, the Davos Communications Awards honor the best teams and campaigns in the industry that have leveraged insights and innovation to achieve measurable business outcomes. A distinguished jury of leading communications experts reviewed nearly 100 entries from over 20 countries across Europe, Asia, South America, North America, and Africa.

BGI Genomics IG posts related to breast cancer and cervical cancer
BGI Genomics IG posts related to breast cancer and cervical cancer

The Instagram Campaign (Gold) award recognizes the company's efforts to create a community to make life science and healthcare tips more accessible to younger audiences through engaging short videos, fun facts, and quizzes. Key themes covered in these 104 posts included scientific research findings, science-based tips for healthier living, and the importance of cancer screening.

"This year's entries have truly set a remarkable standard, offering nothing but excellence in communications. We've witnessed campaigns that not only met but exceeded industry benchmarks, demonstrating a keen understanding of the ever-changing communications landscape", said the Jury Chair Arun Sudhaman, CEO & Editor-in-Chief at PRovoke Media.

Dara Wang, PR Director, BGI Genomics, notes: "Our IG account won over 55,000 fans in 2022, with around 275,000 engagements and over 8,300 shares. Recognition at the Davos Communication Awards will motivate BGI Genomics to be more committed to science communication, bridge the knowledge gap between scientific discoveries and the general public—particularly with younger audiences—and raise awareness of genetic disease screening and management."

The deliberative awards application process provided fresh insights for future cancer screening campaigns to sharpen the company's focus on enhancing health outcomes through greater accessibility and affordability. This collaborative process further validated that biotech communications can be inclusive, light on jargon, and unintimidating to general audiences seeking to enhance their health. 

"The Davos Communications Awards represent a global celebration of innovation, creativity, and public relations and communications excellence. The impressive entries we receive each year from around the world highlight our industry's evolving landscape and its crucial role in shaping narratives and fostering connections across borders", said Maxim Behar, President of the World Communications Forum Association.

About BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading provider of integrated solutions for precision medicine. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

As of December 2022, the company has published over 440 SCI or Science Citation Index papers in cancer research, with a cumulative impact factor of over 4,000 points. A consistent number of important papers have been published in Nature Medicine, Cell, Nature, Science, Nature Genetics, and other top scientific journals.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.